Holen Sie sich die Stockscreener-App
37.11
1.56%
0.57
Handel nachbörslich:
36.43
-0.68
-1.83%
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Melissa Epperly Receives 513 Roivant Shares, Retains 15,351 After Tax Withholding Net Settlement - Kalkine Media
Taxes account for 116 shares of a 513-share director award at Roivant Sciences (ROIV). - Stock Titan
An 810-share award is fully vested for Roivant Sciences (ROIV) director Oren Ilan. - Stock Titan
A director receives 383 Roivant Sciences (ROIV) shares, with 77 withheld for taxes. - Stock Titan
Planned share sales at Roivant Sciences (ROIV) include 14,144 shares at $35.42. - Stock Titan
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - GlobeNewswire Inc.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) - GlobeNewswire Inc.
Form 144 Roivant Sciences Ltd. For: 20 October By Investing.com - Investing.com Nigeria
19,976 shares withheld for taxes leave Roivant Sciences (ROIV) CIO holding 18.6M shares. - Stock Titan
At $33.53 each, 34,638 shares were withheld for CEO taxes at Roivant Sciences (ROIV). - Stock Titan
An officer proposes selling 200,000 Roivant Sciences (NASDAQ: ROIV) shares under a trading plan. - Stock Titan
Roivant Sciences (ROIV) Tests Brepocitinib Hopes As The Stock Looks Fully Valued - Simply Wall Street
Form 144 Roivant Sciences Ltd. For: 20 October By Investing.com - Investing.com South Africa
Roivant Sciences (ROIV) Rises 3.07% to $34.56, Trading Near Midpoint of Support and ResistanceVirgin POC - https://www.dars.gov.et/
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run - Yahoo Finance
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. - Stock Titan
Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares. - Stock Titan
CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes. - Stock Titan
Vesting triggers withholding of 46,879 shares from Roivant Sciences (ROIV) President Mayukh Sukhatme. - Stock Titan
After exercising $3.85 options, Eric Venker sells shares in Roivant Sciences (ROIV). - Stock Titan
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Nigeria
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant (ROIV) director uses shares to cover taxes - Stock Titan
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
0.70%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):